An experimental drug might help slow early Alzheimer’s disease in a markedly different way than today’s treatments—by lowering levels of a brain protein called tau, researchers reported Tuesday.
An analysis of the brain of a deceased Alzheimer’s disease (AD) clinical trial participant found that regions where an anti-amyloid therapy successfully cleared amyloid plaques showed little to no evidence of tau tangles, a hallmark of AD closely linked to neurodegeneration and cognitive decline.
With the aid of physical forces—in this case, sound—it is possible to actively steer the formation of engineered tissue. For example, sound waves can be used to create functional vascular networks with blood vessel-like structures in vitro. Scientists at the Center for Molecular Biology of Heidelberg University have demonstrated this through their methodology for acoustic manipulation. The team led by Junior Professor Dr. Daniela Duarte Campos also defines quality requirements for generating complex vascularized 3D tissue containing multiple cell types that is relevant, for example, to biomedical studies.
Wearable devices have transformed how people track exercise, sleep, heart rate and other vital signs. Researchers at King Abdullah University of Science and Technology (KAUST) are now exploring whether similar technologies could one day help monitor medicines inside the body.
More than 100,000 people in the United States are waiting for a lifesaving organ transplant. For patients who need a liver transplant, determining whether a donor liver is healthy enough to transplant is a critical part of the process.
A breakthrough combination of new silicone materials and advanced 3D printing technology developed by University of Waterloo researchers could transform how contact lenses are manufactured.
Disease progression in people with Parkinson’s disease can be accurately monitored using sensors, removing some of the limitations of wearable technologies, a new study reports.
Scientists can use patient-derived tissue samples to grow miniature versions of human organs, allowing them to test new medications and disease treatments for personalized care.
STOCKHOLM, July 13, 2026 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection (US brand name: Leqembi Iqlik®) as a starting dose for the treatment of early Alzheimer’s disease. The US launch is planned for late August 2026.
To develop new and better peptides, the short amino acid strings behind medicines like GLP-1 drugs, researchers have used AI to generate candidates and to predict their properties.